Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,175 trials

NCT07227571
Recruiting
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Phase 1 · United States · 1 site
Registry update: 1 Sept 2026
NCT07315061
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Phase 2 · China · 1 site
Registry update: 22 Apr 2026
NCT07287345
Recruiting
Colchicine's Effect on Inflammatory Markers
Phase 4 · United States · 1 site
Registry update: 25 Jun 2026
NCT07195695
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Phase 3 · Argentina, Austria, Australia, Belgium, Brazil, Canada, Chile, China, Germany, Denmark, Spain, France, United Kingdom, Greece, Hong Kong, Israel, Italy, Japan, South Korea, Mexico, Netherlands, Portugal, Romania, Sweden, Singapore, Taiwan, United States · 204 sites
Registry update: 2 Nov 2026
NCT07356154
Recruiting
A Study of Revumenib and Mezigdomide in People With Leukemia
Phase 1/2 · United States · 10 sites
Registry update: 20 Oct 2026
NCT07258771
Recruiting
Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
Phase 4 · United States · 1 site
Registry update: 2 Feb 2026
NCT06417190
Recruiting
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Phase 2 · United States · 1 site
Registry update: 6 Aug 2026
NCT07222215
Recruiting
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · United States · 1 site
Registry update: 26 Aug 2026
NCT07235293
Recruiting
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Phase 2 · Australia, United States · 18 sites
Registry update: 20 Aug 2026
NCT07053800
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Phase 2 · Brazil, United Kingdom, Greece, United States, Vietnam · 16 sites
Registry update: 30 Oct 2026
NCT07246408
Recruiting
Intermittent Cottonseed Oil Consumption
Not applicable · United States · 1 site
Registry update: 9 Sept 2026
NCT07192120
Recruiting
A Study of MHB048C in Patients With Advanced Solid Tumors
Phase 1/2 · China · 1 site
Registry update: 9 Apr 2026
NCT06594068
Recruiting
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
Phase 4 · United States · 1 site
Registry update: 16 Sept 2026
NCT06707493
Recruiting
Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 · United States · 7 sites
Registry update: 5 Oct 2026
NCT07402954
Recruiting
Stimulation of External Carotid Artery Circulation
Not applicable · United States · 1 site
Registry update: 20 Feb 2026
NCT07694674
Recruiting
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Not applicable · China · 1 site
Registry update: 10 Jul 2026
NCT07713797
Recruiting
Biomarkers for Endometriosis
Not applicable · Canada · 1 site
Registry update: 3 Aug 2026
NCT07724223
Recruiting
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
Phase 2 · China · 1 site
Registry update: 24 Jul 2026
NCT07370675
Recruiting
Active Surveillance for Bethesda IV Thyroid Nodules
Not applicable · Denmark · 1 site
Registry update: 27 Jan 2026
NCT07227831
Recruiting
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Not applicable · United States · 8 sites
Registry update: 26 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.